The FDA said Sept. 17 that investigators inspected the compounding pharmacy in July and August and found conditions which could cause the compounded drugs to be contaminated or otherwise pose risks to patients.
Using non-sterile drug products that are intended to be sterile could cause serious, potentially life-threatening infections or death, the agency warned.
Greenpark recalled several lots of its compounded ophthalmic drugs in August. The FDA later recommended the pharmacy expand its recall to all unexpired compounded drugs intended to be sterile and to stop production until it implements corrective actions, but the pharmacy has refused to do so, according to the agency.
Healthcare providers and patients should check their medical supplies and immediately stop using any products marketed as sterile from Greenpark Compounding Pharmacy, the FDA said.
The agency isn’t aware of any adverse reactions to Greenpark’s compounded drug products.
Read the FDA’s full news release here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
